| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11654106 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(13 years from now) | |
| US11369567 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(13 years from now) | |
Atorvaliq is owned by Cmp Dev Llc.
Atorvaliq contains Atorvastatin Calcium.
Atorvaliq has a total of 2 drug patents out of which 0 drug patents have expired.
Atorvaliq was authorised for market use on 01 February, 2023.
Atorvaliq is available in suspension;oral dosage forms.
Atorvaliq can be used as as an adjunct to diet to reduce low-density lipoprotein cholesterol in adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia; as an adjunct to other low-density lipoprotein cholesterol (ldl-c) lowering therapies, or alone if such treatments are unavailable, to reduce ldl-c in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia.
The generics of Atorvaliq are possible to be released after 07 June, 2037.
Drugs and Companies using ATORVASTATIN CALCIUM ingredient
Market Authorisation Date: 01 February, 2023
Treatment: As an adjunct to diet to reduce low-density lipoprotein cholesterol in adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia; As an adjunct to other low...
Dosage: SUSPENSION;ORAL
ATORVALIQ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic